DIRS.INFO The most relevant business & tech news

☆ Goldman says buy this under-the-radar biopharma stock expected to rally nearly 80%
▼ + stars: | 2022-10-20 | by ( Samantha Subin | ) www.cnbc.com time to read: +1 min

This little-known California-based biopharmaceutical stock can see its shares rally nearly 80% in the near term, according to Goldman Sachs. Shares of the company's stock were up more than 5% in trading Thursday on the back of Choi's call. The analyst also sees promise in the company's pipeline of Bruton's tyrosine kinase inhibitor drugs, currently in the works to treat a slew of conditions including some forms of lymphoma and potentially multiple sclerosis. The bank's price target suggests shares can soar another 78% from Wednesday's close. "We are broadly bullish on GOSS's pipeline and view the risk/reward profile at current levels as favorable," he said.

☆ Regulatory approvals for AbbVie, J&J bolster the Club investment case
▼ + stars: | 2022-10-20 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +5 min

The technology platform — called Teligen — was developed by DePuy Synthes, a J & J subsidiary under the medical technology umbrella. J & J said Thursday it expects Teligen to be available in the U.S. later this year. J & J CEO Joaquin Duato, who took over the role earlier this year, has spoken about the complementary nature of the med tech and pharmaceutical divisions. That's where Johnson & Johnson is going to play, in that intersection. We like owning J & J for its defensive characteristics right now, while all three divisions are under the same roof.

☆ Sartorius shares drop as it tempers 2022 revenue ambitions
▼ + stars: | 2022-10-19 | by ( ) www.reuters.com time to read: +2 min

"We are specifying our full-year outlook for 2022 within the range projected so far, but the global political and economic uncertainties remain high," said Chief Executive Joachim Kreuzburg. Orders were below expectations, analysts at JP Morgan said, adding that was "unlikely to reduce lingering concerns over the outlook for 2023". Analysts on average expect 4.7 billion euros in sales next year, a year-on-year gain of about 12%, according to Refinitiv data. Sartorius has projected roughly 10% annual sales growth through 2025, or about 14% when excluding the expected drop in business related to the coronavirus as drugmakers embrace new high-tech methods such as mRNA, cell therapies and more complex therapeutic proteins. Underlying earnings before interest, taxes, depreciation and amortisation (EBITDA) rose 21.4% to 1.05 billion euros in the first nine months, broadly in line with market expectations.

☆ U.S. sends experimental antibody, antiviral drug to Uganda for Ebola outbreak
▼ + stars: | 2022-10-18 | by ( Julie Steenhuysen | Nancy Lapid | ) www.reuters.com time to read: +3 min

There are currently no proven vaccines or treatments for the Sudan species of Ebola, one of four known Ebola viruses to cause hemorrhagic fever in humans. The outbreak confirmed by the Ugandan health ministry on Sept. 20 is the largest of the Sudan species since 2000. "If healthcare workers start to fall ill and die, it's going to negatively impact the response," said Montgomery, who had just returned from a trip to Uganda. For instance, healthcare workers may be reluctant to assist in the response, he said in a phone interview. A large outbreak of the Zaire species of Ebola in West Africa from 2014-2016 led to effective vaccines and treatment, but there are no proven treatments or vaccines for the Sudan species.

☆ Don’t let the volatility 'scare you out of stocks’: Market veteran reveals what to buy right now
▼ + stars: | 2022-10-14 | by ( Zavier Ong | ) www.cnbc.com time to read: +4 min

But market veteran Nancy Tengler is unequivocal that investors should strap in for the long term. Her firm uses what's known as a relative dividend yield (RDY) strategy to judge the value of a stock. A high relative dividend yield is a buy signal if the dividend level is expected to be sustained and increased over time. "If you can get 17% annualized dividend growth, as Home Depot has produced over the last five years, that's a pretty good hedge against inflation. The company has a dividend yield of about 4% and an annualized dividend growth of 17% over the past five years, according to Tengler.

☆ Stocks making the biggest moves midday: Digital World, Domino's, Revlon, Albertsons and more
▼ + stars: | 2022-10-13 | by ( Alex Harring | ) www.cnbc.com time to read: +5 min

It was a 52-week low for the stock. Applied Materials – The chip stock turned 4% higher after hitting a 52-week low earlier on disappointing revenue outlook. Otonomy — The biopharmaceutical company shot down 56.1% after the company said a drug for hearing loss showed "no clinically meaningful improvement." Dish Network — The TV and wireless company hit a 52-week low, down 2%. The stock was at a 52-week low during day trading.

☆ Factbox: Companies sell their businesses in Russia
▼ + stars: | 2022-10-10 | by ( ) www.reuters.com time to read: +9 min

The logo of French tyre maker Michelin is seen at a company building in Boulogne-Billancourt, near Paris, France, August 6, 2022. REUTERS/Sarah Meyssonnier/File PhotoOct 10 (Reuters) - Some Western companies have agreed to sell their Russian assets or hand them over to local managers as they seek to comply with sanctions over the Ukraine conflict and deal with threats from the Kremlin that foreign-owned assets may be seized. Below is a list of firms by sector that have sold their businesses in Russia:AUTOS** British car distributor Inchcape (INCH.L) sold its Russian business to local managementRegister now for FREE unlimited access to Reuters.com Register** Italian truck and bus maker Iveco (IVG.MI) transferred its 33% stake in its AMT truck assembly joint venture in Russia to a local partner** French tyre maker Michelin (MICP.PA) intends to transfer its activities in Russia to a new entity under local management by end-2022** French carmaker Renault (RENA.PA) sold its majority stake in Avtovaz (AVAZI_p.MM) to a Russian science institute, and transferred all shares in Renault Russia to the city of Moscow** MAN Truck & Bus and Scania, units of German truck maker Traton (8TRA.DE), expect to sell their sales companies in Russia to local partners along with Scania's Russian financing business by Q1 2023BANKS** Britain's HSBC (HSBA.L) agreed to sell its Russian business to Expobank, subject to regulatory approvals in Russia** Czech investment group PPF sold its Russian banking assets, including consumer lender HCFB and its subsidiaries, to investors led by Ivan Tyryshkin** France's Societe Generale (SOGN.PA) sold its Russian business Rosbank (ROSB.MM) to Interros Capital, a firm linked to Russian oligarch Vladimir PotaninCONSUMER ELECTRONICS** Swedish home appliance maker Electrolux (ELUXb.ST) transferred its business in Russia to local management** Its Electrolux Professional (EPROb.ST) branch also sold its Russian business to local management** Whirlpool (WHR.N) sold its Russian operations to Turkey's Arcelik (ARCLK.IS)ELECTRICAL COMPONENTS & EQUIPMENT** Finland's Boreo (BOREO.HE) sold its 90% stake in YE Russia to companies controlled by its current director Yrjö Pönni** U.S. industrial firm Emerson Electric (EMR.N) agreed to sell its Russia business to the local management** Finnish elevator maker Kone (KNEBV.HE) expects to close the sale of its Russian business to local management in Q4 2022** France's Schneider Electric (SCHN.PA) expects to close the sale its Russian unit to local management by end-2022** U.S. elevator maker Otis (OTIS.N) sold its Russia business to local investment firm Ice DevelopmentENERGY** French industrial gases producer Air Liquide (AIRP.PA) agreed to shift its Russian assets to local management, subject to regulatory approvals in Russia** Baker Hughes (BKR.O) agreed to sell its oilfield services business in Russia to local management, with closing expected in H2 2022** Italian utility Enel (ENEI.MI) sold its 56.43% stake in Enel Russia to Lukoil (LKOH.MM) and private fund Gazprombank-Frezia** Norway's Equinor (EQNR.OL) transferred assets of its Russian oil and gas joint ventures to state-owned partner Rosneft (ROSN.MM), and its 30% stake in the Arctic Kharyaga oilfield to state-controlled Russian operator Zarubezhneft** U.S. oilfield services firm Halliburton (HAL.N) sold its Russia operations to a management team made up of former employees** Oil major Shell (SHEL.L) sold its Russian retail and lubricants business to Lukoil** Singapore-based commodities trader Trafigura sold its 10% stake in Vostok Oil project in Siberia to Hong Kong-registered trading firm Nord Axis** Total Energies (TTEF.PA) sold its remaining 20% interest in the Kharyaga oil project to Zarubezhneft, and its 49% stake in Terneftegaz to joint venture partner NovatekFOOD & BEVERAGES** Finland's Atria (ATRAV.HE) sold its fast food business in Russia, Sibylla Rus, to Russian meat producer Cherkizovo (GCHE.MM)** Finland's Fazer sold its Russian unit to Moscow's Kolomenskij Bakery and Confectionery Holding** Irish ingredients giant Kerry Group (KYGa.I) sold its Russian subsidiary to local management and agreed to offload its Belarusian unit to a local operator** Fast food chain McDonald's (MCD.N) sold its Russian business to its licensee Alexander Govor** Finnish food and drinks company Paulig sold its operations in Russia to private Indian investor Vikas Soi** Yum Brands (YUM.N) sold its Pizza Hut business in Russia to a local operator** Finnish food processing firm Raisio (RAIVV.HE) sold its consumer business in Russia to Copacker Agro** Finnish dairy producer Valio sold its Russian business to GK VelkomINDUSTRIAL MACHINERY** Polish measuring devices maker Apator's (APTP.WA) Powogaz unit divested its entire stake in Russia-based AO Teplovodomer** Danish industrial firm Danfoss agreed to sell its Russian and Belarusian business to local management, subject to approval by shareholders and regulatory approvals in Russi

☆ Stocks making the biggest moves midday: Apple, Netflix, Biogen, Canopy Growth and more
▼ + stars: | 2022-09-28 | by ( Tanaya Macheel | ) www.cnbc.com time to read: +2 min

Apple — Apple shares fell 3.4% on Wednesday following a report that the company is ditching plans to boost new iPhone production. Instead of aiming to increase output by 6 million units in the second half of the year as it had planned, it will shoot for 90 million units, unchanged from the prior year, according to Bloomberg. Biogen — Shares of the biopharmaceutical company soared 37% following upbeat results from its experimental Alzheimer's drug study and a slew of upgrades from analysts. Biogen and its Japanese partner Eisai said the drug reduced cognitive decline by 27% and slowed the progression of the disease. Canopy Growth — Shares of the cannabis company were up 2.6% on plans to pull back from its retail operations in Canada.

☆ The mRNA vaccine transformed Pfizer. Here's how the biopharma giant plans to retain its new 'light-speed mentality' and create drugs faster.
▼ + stars: | 2022-09-23 | by ( Marguerite Ward | ) www.businessinsider.com time to read: +6 min

The biopharmaceutical giant, along with its partner BioNTech, was one of the first to develop a marketable vaccine for COVID-19 using nascent mRNA technology. mRNA technology has tremendous potential for other disease areas such as oncology and rare diseases. We've just started our phase-three study of a quadrant flu vaccine made out of mRNA. We see it has several advantages over current flu vaccines, including higher efficacy. A Pfizer senior vice president said mRNA technology could transform vaccines for the flu and lead to breakthroughs in cancer treatment.

☆ 3 of our stocks are in the news — here's our take on what's happening
▼ + stars: | 2022-09-21 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +10 min

Scharf, who took over the troubled lender in October 2019, said in his congressional testimony Wednesday that Wells Fargo has "approximately $1.9 trillion in assets." The Club take: Our investment thesis in Wells Fargo largely rests on a two-pronged approach to boost earnings. As rates rise, Wells Fargo can make more money on the spread between what it pays customers for deposits and what it charges for loans. Still, intensifying recession fears have ultimately been a drag on Wells Fargo shares this year. Investors must be realists, though, and our stake in Wells Fargo never assumed it would be a quick fix.

☆ People: Employees' well-being, diversity, and equity are key components of sustainability
▼ + stars: | 2022-03-03 | by ( Sharon Goldman | ) www.businessinsider.com time to read: +5 min

Sustainable goals include improving people's well-being, health, and equity. This article is part of the "Financing a Sustainable Future" series exploring how companies take steps to set and fund sustainable goals. That includes investing in everything from fair wages to reskilling and upskilling; health and safety; diversity, equity, and inclusion; gender equality; and fair hiring practices. For Horizon Therapeutics, a biopharmaceutical company with 1,800 employees worldwide, a key priority around diversity, equity, and inclusion is pay equity. "We have 100% pay equity at Horizon,'' said Irina Konstantinovsky, Horizon's executive vice president, chief human-resources officer, and chief diversity officer.

☆ Cerebral is trying out an unusual clinical trial for a depression drug that has other companies wary. Here’s why.
▼ + stars: | 2022-01-14 | by ( Megan Hernbroth | ) www.businessinsider.com time to read: +6 min

The mental-health startup Cerebral partnered with Alto Neuroscience for a clinical trial. The mental-health startup Cerebral is teaming up with Alto Neuroscience on an upcoming home-based clinical trial for the biopharmaceutical company Alto's depression-drug candidate, according to federal records. The idea behind the partnership is that Cerebral is a mental-health company treating patients with depression, the condition for which Alto is developing treatments. Cerebral Chief Medical Officer David Mou told TechCrunch in December that the startup provided patients for the trial "within an hour." How Alto is running the trialThe trial with Cerebral does not include a control group, according to the filing.

☆ SCOOP: Sen. Dianne Feinstein fails to disclose husband's stock purchase, says she's willing to pay a fine
▼ + stars: | 2021-01-27 | by ( Dave Levinthal | ) www.businessinsider.com time to read: +5 min

Sen. Dianne Feinstein's husband, investment banker Richard Blum, invested up to $50,000 in polling firm The Generation Lab. But the Democratic lawmaker didn't disclose the purchase until this month, weeks after a federal deadline. Feinstein has not yet been contacted by the Senate Ethics Committee on whether she will face a fine, Mentzer added. Members of Congress are generally allowed to buy and sell individual stocks — to the chagrin of some government reform advocates — so long as they publicly disclose the transactions. Not until May did Feinstein publicly disclose her husband's Facebook stock purchase, investigative journalism outfit Sludge revealed later in 2018.

☆ Laboratorul chinez Sinovac a obţinut o finanţare de 500 de milioane de dolari pentru producerea vaccinului anti-COVID
▼ + stars: | 2020-12-07 | by ( Publika.Md - Aici Sunt Știrile | ) www.publika.md time to read: +1 min

Banii vor fi investiţi de grupul chinez Sino Biopharmaceutical, cu sediul la Beijing şi cotat la bursa din Hong Kong, iar Sinovac a explicat că vor fi folosiţi la extinderea cercetărilor şi capacităţii de producţie a vaccinului, denumit CoronaVac.Până la sfârşitul anului se intenţionează producerea a 600 milioane de unităţi, iar în schimbul investiţiei Sino Biopharmaceutical va primi 15% din capitalul unei filiale a Sinovac, Sinovac Life Sciences.Vaccinul se află încă în faza a treia a testelor clinice în mai multe ţări, între care Brazilia, iar organismul chinez de reglementare în domeniu încă nu a dat undă verde comercializării produsului.Patronul Sinovac, Yin Weidong, a subliniat luni într-un comunicat că acesta "a atins o etapă foarte importantă în testele clinice din Asia şi America Latină".Beijingul a început deja să administreze vaccinuri anumitor categorii de persoane considerate prioritare, în special personal sanitar, diplomaţi, angajaţii sau studenţii care urmează să plece în străinătate.Aproape un milion de persoane au fost deja inoculate cu ajutorul unui alt vaccin chinezesc experimental produs de compania concurentă Sinopharm, a anunţat aceasta luna trecută.Marea Britanie a devenit săptămâna trecută prima ţară occidentală care a dat undă verde distribuţiei generale a unui vaccin anti-coronavirus, cel pus la punct de companiile americană Pfizer şi germană BioNTech, vaccinarea urmând să debuteze marţi.La rândul ei, Rusia a început vaccinarea anumitor categorii cu vaccinul său Sputnik V, aminteşte AFP.

Persons: Sinovac Locations: Beijing, Hong Kong, Sinovac, Brazilia, Asia, America Latină, Rusia

Search resuls for: "Biopharmaceutical"

14 mentions found